Your Followed Topics

health6h ago

Key facts: Pfizer reports reduced death risk in prostate cancer; lung cancer therapy shows long-term survival

Key facts: Pfizer reports reduced death risk in prostate cancer; lung cancer therapy shows long-term survival Open in Tradingview.com
Highlights
  • Pfizer reports a 40% lower death risk in advanced prostate cancer with Xtandi plus leuprolide versus leuprolide alone.
  • The EMBARK Phase 3 study showed a 40% lower death risk for advanced prostate cancer when Xtandi is combined with leuprolide.
  • The report notes ongoing long-term survival benefits for advanced lung cancer with Braftovi and Mektovi.

Virality Score Timeline

Vote 0
0

Related Topics

0 Comments

Be the first to comment

Add your thoughts and get the conversation going.

Top 564 Internet News Today

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.